Dr. Melissa Johnson, MD
Claim this profileSarah Cannon Research Institute
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
66 reported clinical trials
94 drugs studied
About Melissa Johnson, MD
Education:
- Awarded the Morehead-Cain Scholarship at the University of North Carolina, Chapel Hill.
- Obtained an MD (Doctor of Medicine) from the University of Pennsylvania.
Experience:
- Served as Chief Fellow for one year at an unspecified institution.
- Co-founded the Northwestern Medical Developmental Therapeutics Institute.
- Since 2014, has been with the Sarah Cannon Research Institute at Tennessee Oncology, now the Associate Director of Lung Cancer Research.
- Focuses on expanding phase II and III lung cancer clinical trials and developing early-phase compounds for thoracic cancers.
Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage III
EGFR positive
2Non-Small Cell Lung Cancer
Global LeaderStage IV
Stage III
EGFR positive
Affiliated Hospitals
Clinical Trials Melissa Johnson, MD is currently running
BDTX-1535 + Temozolomide
for Glioblastoma and Lung Cancer
BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), optimal dosage, central nervous system (CNS) activity, and antitumor activity of BDTX-1535. The study population comprises adults with either advanced/metastatic non-small cell lung cancer (NSCLC) with non-classical or acquired epidermal growth factor receptor (EGFR) resistance (EGFR C797S) mutations with or without CNS disease (in Phase 1 and Phase 2), or glioblastoma (GBM) expressing EGFR alterations (Phase 1 only). All patients will self-administer BDTX-1535 monotherapy by mouth in 21-day cycles. Phase 1 enrollment is now complete. Phase 2 is currently enrolling.
Recruiting1 award Phase 1 & 214 criteria
IMM-1-104
for Solid Cancers
This trial is testing a new drug called IMM-1-104 to see if it can help treat advanced cancers with specific genetic changes. The drug works by blocking signals that make cancer cells grow.
Recruiting1 award Phase 1 & 2
More about Melissa Johnson, MD
Clinical Trial Related6 years of experience running clinical trials · Led 66 trials as a Principal Investigator · 21 Active Clinical TrialsTreatments Melissa Johnson, MD has experience with
- Pembrolizumab
- Atezolizumab
- Docetaxel
- Carboplatin
- Nivolumab
- Osimertinib
Breakdown of trials Melissa Johnson, MD has run
Lung Cancer
Non-Small Cell Lung Cancer
Solid Tumors
Uterine Tumors
Skin Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Melissa Johnson, MD specialize in?
Is Melissa Johnson, MD currently recruiting for clinical trials?
Are there any treatments that Melissa Johnson, MD has studied deeply?
What is the best way to schedule an appointment with Melissa Johnson, MD?
What is the office address of Melissa Johnson, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.